0114 QT Reg
BioCentury & Getty Images

Regulation

Jan. 14 Quick Takes: Lexicon rises on NDA timeline for heart failure program; plus: FDA COVID reports and updates from BeiGene, Merck, Bayer

Jan 15, 2021 | 2:54 AM GMT

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) gained $4.13 (105%) to $8.05 Thursday after saying data from its

Read the full 483 word article

How to gain access

Continue reading with a
two-week free trial.